BeaconEquity.com announces the publication of an article covering recent news from International Stem Cell (OTCBB: ISCO), including the company receiving favorable results from animal trials conducted to improve photorefractive keratectomy (PRK).
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“International Stem Cell Corp., a “parthenogenetic” stem-cell research company, recently announced it received favorable results from animal trials conducted to improve photorefractive keratectomy (PRK), a corrective laser surgery offering as an alternative to LASIK. Future trials for the company's advanced stem-cell technology offer a potential breakthrough to patients suffering from various eye pathologies requiring laser eye surgery.”
PRK Laser Surgery has the potential to replace LASIK, according to International Stem Cell:
“Eye surgeons believe PRK offers a safer and better long-term outcome than LASIK, but is not the procedure of choice due to increased patient discomfort and longer healing times involved with PRK. The Oceanside, Calif.-based company stated in a news release by combining ISCO's proprietary device developed by Paul Chen, M.D., conductor of the trials, and the company's human corneal cells, the hundreds of thousands of LASIK procedures performed each year will be replaced by the company's advanced stem cell technology.”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s market news is one of the fastest growing small-cap blogs in the investment community. Beacon is the authority on research in the small-cap sector, and our analysts strive each day to find the stocks poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
